Examples of using Bayer expects in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Bayer expects a record year in 2007.
Based on current assumptions about the equity andfinancing measures to be undertaken, Bayer expects a moderate decline in core earnings per share.
Bayer expects a record year in 2007 more.
Sales and earnings in 2018 expected to be at the prior-year level despite currency lossesBased on the exchange rates as of December 31, 2017, Bayer expects sales of around 35 billion euros for 2018.
Bayer expects a significant profit increase next year.
Moreover, adjusted for divestments, Bayer expects synergies to deliver annual contributions of 1.2 billion U.S. dollars to EBITDA before special items as of 2022.
Bayer expects to close the transaction during the first quarter of 2014.
Despite declining price developments in some areas, Bayer expects sales of approximately EUR 16 billion(2015 pro forma: EUR 15,308 million) in the Pharmaceuticals Division including the Radiology business.
Bayer expects the bond to favorably influence Lanxess' credit rating.
Beyond the attractive longterm value creation potential of the combination, Bayer expects the transaction to provide its shareholders with accretion to core EPS(earnings per share) in the first full year after closing and a double-digit percentage accretion in the third full year.
Bayer expects to complete the acquisition in the first quarter of 2014.
At Crop Science, Bayer expects sales to be at the prior-year level 2015: EUR 10,367 million.
Bayer expects net financial debt to be below EUR 16 billion at the end of 2016.
At Animal Health, Bayer expects sales slightly above the prior-year level 2015: EUR 1,490 million.
Bayer expects this figure to rise further to more than EUR 4 billion in 2015.
At the same time, Bayer expects the new process to provide economic advantages over the conventional production method.
Bayer expects to generate gross proceeds of 6.0 billion euros from the capital increase.
In the Consumer Health Division, Bayer expects sales to come in at more than EUR 6 billion and plans to grow sales by a mid-single-digit percentage on a currency- and portfolio-adjusted basis 2015 pro forma: EUR 6,076 million.
Bayer expects this interdisciplinary research to provide additional growth impetus in the long term.
Bayer expects annual turnover potential of 2 billion Euros from the new anticoagulant drug.
In 2016, Bayer expects to achieve sales of approximately EUR 35 billion in the Life Science businesses, in other words excluding Covestro.
Bayer expects additional marketing and R& D expenditures in Pharmaceuticals to amount to some EUR 0.5 billion in 2014.
Bayer expects the transaction to add to its earnings in 2006, and to have an estimated negative impact of 118 million euros on earnings before interest and taxes(EBIT) in the first quarter of 2005.
Bayer expects this capital increase to be smaller than originally planned because the proceeds from the sale of Covestro shares were higher than initially anticipated.
Bayer expects that, in the course of the remaining governmental proceedings and civil actions, additional expenses will become necessary that may also be of material importance to the company.
Bayer expects all its suppliers and subcontractors to share our commitment to high ethical standards and to operate in a responsible and ethical manner towards their employees and their own suppliers.
Bayer expects the positive market environment for its CropScience business to be maintained in the fourth quarter, Wenning added, confirming the raised target announced in August of increasing the EBITDA margin before special items to more than 22 percent for the full year 2007.
Bayer expects a positive contribution to core earnings per share starting in 2019. From 2021 onward, that contribution is expected to be double-digit percentage. Moreover, adjusted for divestments, Bayer expects synergies to deliver annual contributions of 1.2 billion U.S. dollars to EBITDA before special items as of 2022.
Bayer MaterialScience expects demand for this precursor for flexible polyurethane foams to continue to grow.
Bayer CropScience expects the measures to be accretive to EBIT after special items starting in 2008.